PhoreMost it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park, designed to support PhoreMost’s phenotypic screening requirements and expertise.
The new facility enables the company to add in-house flow cytometry and imaging capabilities.
Dr Chris Torrance, CEO of PhoreMost, said: “Our move to Unity Campus follows a significant year for the company, including a successful £33M Series B investment round in March 2021. As a team, remaining within the Cambridge biotech cluster is important, to help fuel new strategic collaborations, and support those already in progress. This move brings the whole team together in one site, where previously we were split across two buildings. With further space available at Unity Campus, we are well-positioned to continue to advance and expand our drug discovery programmes across high value, but under-served, therapeutic areas.”